['respiratory syncytial virus infections']
['medi8897', 'placebo']

        Key Inclusion Criteria:

          1. Healthy infants born between 29 weeks 0 days and 34 weeks 6 days GA.

          2. Infants who are entering their first full RSV season at the time of screening.

        Key Exclusion Criteria:

          1. Meets American Academy of Pediatrics (AAP) or other local criteria to receive
             commercial palivizumab.

          2. Any fever (>= 100.4°F [>= 38.0°C], regardless of route) or lower respiratory illness
             within 7 days prior to randomization.

          3. Acute illness (defined as the presence of moderate or severe signs and symptoms) at
             the time of randomization.

          4. Active RSV infection (a child with signs/symptoms of respiratory infection must have
             negative RSV testing) or known prior history of RSV infection.

          5. Receipt of palivizumab or other RSV monoclonal antibody or any RSV vaccine, including
             maternal RSV vaccination.
      